Skip to content
akaturk Academic measurement
Sign in Register

Academician

BİLGİN DEMİR

DOKTOR ÖĞRETİM ÜYESİ (Unvan:Doçent)

AYDIN ADNAN MENDERES ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Tıbbi Onkoloji (İç Hastalıkları)

A quick look at recorded outputs — details below.

  • Articles 31
  • Projects 0
  • Books 0
  • Proceedings 0
  • Patents 0
  • Artistic 0
Scopus (SJR) Q1 11 Q2 9 Q3 3 Q4 1
WoS (JCR) Q1 7 Q2 7 Q3 6 Q4 4
TR Index 4 articles

Field+year+type normalized OpenAlex percentiles — not Clarivate ESI / SciVal.

Top 1% articles 0
Top 10% articles 2
Avg percentile 53.6%
Top 1% share 0.0%
Top 10% share 6.7%

Articles

Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.

Index filters

31 publications total

Scopus (SJR)
Q1 11 Q2 9 Q3 3 Q4 1
WoS (JCR)
Q1 7 Q2 7 Q3 6 Q4 4
TR Index
4 articles

Article list

  1. 2026 An Experimental Study on the Widely Used Chemotherapeutic Docetaxel: Does It Induce Inflammation, Ischemia, and Neurodegeneration in the Eye, Causing Dry Eye and Blurred Vision in a Real-Life Scenario? Current Eye Research DOI 10.1080/02713683.2025.2575785 YÖKSİS SJR Q2 JCR Q3 OpenAlex 75.9%
  2. 2026 Comparative evaluation of the performance of 18F-PSMA-1007 PET/CT and 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) DOI 10.1016/j.remnie.2025.500178 YÖKSİS OpenAlex 69.4%
  3. 2026 Evaluación comparativa de los resultados de la PET/TC con [18F]F-PSMA-1007 y la PET/TC con [68Ga]Ga-PSMA-11 en los pacientes con recidiva bioquímica de cáncer de próstata Revista Española de Medicina Nuclear e Imagen Molecular DOI 10.1016/j.remn.2025.500178 YÖKSİS SJR Q4 JCR Q4 OpenAlex 27.6%
  4. 2026 Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group Journal of Clinical Medicine DOI 10.3390/jcm15135224 YÖKSİS SJR Q2 JCR Q1 OpenAlex 61.7%
  5. 2026 Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group CLINICAL & TRANSLATIONAL ONCOLOGY DOI 10.1007/s12094-026-04228-5 YÖKSİS SJR Q2 JCR Q3 OpenAlex 10.9%
  6. 2026 Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy Cancers DOI 10.3390/cancers18142302 YÖKSİS SJR Q1 JCR Q2 OpenAlex 71.8%
  7. 2026 Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis Oncology Research and Treatment DOI 10.1159/000550484 YÖKSİS SJR Q3 JCR Q4 OpenAlex 3.7%
  8. 2026 Comparative Analysis of Trastuzumab-Based Treatment in Advanced Gastric Cancer: Impact of HER2 Expression Levels Meandros Medical And Dental Journal DOI 10.69601/meandrosmdj.1790631 YÖKSİS TR Index JCR Q4 OpenAlex 61.4%
  9. 2025 Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study International Journal of Cancer DOI 10.1002/ijc.70212 YÖKSİS SJR Q1 JCR Q2 OpenAlex 35.0%
  10. 2025 Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study DISCOVER ONCOLOGY DOI 10.1007/s12672-025-03886-1 YÖKSİS SJR Q2 JCR Q3 OpenAlex 80.6%
  11. 2025 Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study Scientific Reports DOI 10.1038/s41598-024-80587-9 YÖKSİS SJR Q1 JCR Q1
  12. 2025 Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer World Journal of Gastrointestinal Oncology DOI 10.4251/wjgo.v17.i5.104341 YÖKSİS SJR Q2 JCR Q3 OpenAlex 86.3%
  13. 2025 CEA and CA 19-9 combined tumor marker index as a prognostic tool for metastatic pancreatic cancer: is two better than one? American Journal of Cancer Research DOI 10.62347/JYAD4332 YÖKSİS SJR Q1 JCR Q2 OpenAlex 22.9%
  14. 2025 Second-line Chemotherapy for Advanced Bladder Cancer: Taxanes Versus Vinflunine Acta Haematologica Oncologica Turcica DOI 10.4274/ahot.galenos.2025.2025-7-2 YÖKSİS TR Index OpenAlex 28.2%
  15. 2025 Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group International Journal of Cancer DOI 10.1002/ijc.70213 YÖKSİS SJR Q1 JCR Q2 OpenAlex 68.3%
  16. 2025 Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer Scientific reports DOI 10.1038/s41598-025-96157-6. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 92.7%
  17. 2025 Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study Medicina DOI 10.3390/medicina61071230 YÖKSİS SJR Q2 JCR Q1 OpenAlex 17.3%
  18. 2025 Prognostic role of eIF2α protein in metastatic renal cell cancer patients Discover Oncology DOI 10.1007/s12672-025-02916-2 YÖKSİS SJR Q2 JCR Q3 OpenAlex 62.4%
  19. 2024 The efficacy of HDDPiW-jSB solution on docetaxel-induced alopecia of rats Cutaneous and Ocular Toxicology DOI 10.1080/15569527.2023.2300790 YÖKSİS SJR Q3 JCR Q3 OpenAlex 68.3%
  20. 2024 The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study Scientific Reports DOI 10.1038/s41598-024-75293-5 YÖKSİS SJR Q1 JCR Q1 OpenAlex 53.9%

Back to academicians